The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Entertainment
  • Marketing
  • Event

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Proper Sky Named to the 2026 MSP 501
  • Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
  • 100+ Episodes In, Liftoff with Keith Newman Tells Founders to Stop Publishing More
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • The Hue Society Expands Roster for the 2026 Wine and Culture Fest
  • Kasinohai Audit: Most Slots Could Be Affected by Finland's Draft Gambling Rules
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • Fig Lehigh Valley Celebrates 50th Edition With Summer Launch Party at the Americus Hotel
  • Make America French Again Launches National Campaign

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Slotozilla Introduces a Centralized Resource for World Cup Bonus Offers
  • Webinar Announcement: Built for Trust: Latitude's 0 to 1 Compliance Playbook for Modern Cross-Border Payments
  • OneVizion Names AI Leader Matthew Kirk as Chief Operating Officer to Drive Governed AI Across Telecom and Electric Utilities
  • Dentists launch independent platform to help practices choose the right technology
  • Contracting Resources Group Recognized by The Daily Record as a 2026 In the Lead: Best Women-Owned Businesses Honoree
  • Woodforest Acceptance Solutions and AlpacaBOSS Launch Partnership
  • New "Lakeside Picnic Ride" Package in Japan's Lake Chuzenji region of Nikko: July 1- November 30, 2026
  • Former MP Shri GV Harsha Kumar Meets AICC President Mallikarjun Kharge
  • Two Attorneys at The Stanley Law Group Named to 2026 South Carolina Super Lawyers List
  • IGH Naturals Announces Peer-Reviewed HuMOLYTE® Study Published in Frontiers in Nutrition
  • LINC to Host CEO Breakfast Forum on July 22
  • The Explorer Shaped Guitar Still a Symbol of Heavy Music with New Releases
  • Allstream Energy Partners Expands AI-Optimized Website Development Division to Meet Growing Demand in GEO / AEO Services
  • Nola Blue announces 'Jumpin' Rockin Rhythm,' the autobiography of Duke Robillard
  • America's Workforce Solution Named an OpenAI SMB Channel Partner, Bringing Enterprise-Grade AI to Main Street
  • Data Tiles Introduces the Decision-Driven Enterprise to North America
  • Disruptor Creations Pioneers New MicroAdventure Series with TravelSpike
  • Hawk Hill Pictures Brings Ukrainian-Language War Drama BUCHA to North American Audiences
  • eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
  • Creative Investment Research Welcomes Supreme Court Decision Protecting Federal Reserve Independence While Calling for Continued Accountability

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 251
  • Dave's Auto Services Sponsors Night of Racing at Action Track USA in Kutztown PA
  • Greensburg Pennsylvania Martial Arts School Racks Up BJJ Wins
  • ReviewsAlly Launches Evidence-Based Review Platform for VPNs, Business Software, and Online Services
  • New Luxury Single Family Homes From $976,990 in Manalapan
  • $150+ Million Contracted Backlog, Strategic Acquisitions Adding Millions In Recurring Revenue, Improving Margins & A Clear Path Toward Profitability
  • Expanding Access to Mental Health Care in Toronto with Dr. Stephen Shainbart
  • CCHR Calls Out Psychiatry's Pattern of Resistance to Antidepressant Deprescribing
  • Bergey's Truck Centers Recognized in 2026 MACH Alliance Composable Impact Awards
  • Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision

Similar on PennZone

  • From DECA Finalist to Translational Scientist: Roohid Parast on Business Training in Biopharma
  • Why More Phoenix Families Are Turning to Private Autopsy Services for Answers
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Record Revenue Growth, AI-Driven Healthcare Innovation, Expanding Proprietary Brand and Targeting $200 Million Revenue By 2029: Cosmos Health Inc
  • Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
  • FDA-Cleared AI Neuropsychiatry Platform, Million-Dose Ketamine Manufacturing and Presidential Psychedelic Initiative Drive Growing Momentum for NRXP
  • Accelerating Toward Commercialization as FDA Momentum, AI Neurotherapy & Manufacturing Expansion Drive Multi-Catalyst Growth Story; N A S D A Q: NRXP
  • Philadelphia Scientist Roohid Parast Advances IBD Research at Johnson & Johnson
  • Medical Experts Highlight the Importance of Second Opinions in Death Investigations
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us